Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal study of split-dose everolimus
NL-OMON21051Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of everolimus and exemestane in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Everolimus pharmacokinetics. Planned start May 2014; status: not yet recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON21051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21051.